Nervous Disorder TRIZ Cases

A propylene glycol-free aerosol liquid balances droplet size, antioxidant protection, and clogging resistance for targeted oral or lung delivery.

A PLGA-based glatiramer depot cuts injection frequency while sustaining release to treat progressive multiple sclerosis with fewer side effects.

Functionally selective D2 ligands bias β-arrestin or cAMP signaling to improve CNS treatment while reducing off-target side effects.

Novel human TREM2 antibodies optimize CDR binding kinetics to inhibit TREM2 signaling, reduce microglia activation, and lower immunogenicity.

Biotin and thiamine supplementation targets SLC19A3-linked metabolic dysfunction to improve motor symptoms and reduce striatal atrophy in Huntington's disease.

A DKP-based lipophilic prodrug extends GLP-1 conversion and terminal half-life while improving oral bioavailability for once-weekly dosing.

Alternating D/L cyclic peptide mimetics improve amyloid fibril binding and support conjugate-based imaging for amyloidogenic disease diagnosis and treatment.

A CBC-first pain formulation excludes THC to deliver analgesia for neuropathic, cancer, and inflammatory pain without psychoactive effects.

Boron ester naloxone variants react with hydrogen peroxide in blood to sustain antagonist release and reduce repeat overdose risk.

Stable TPA023B crystalline salts and co-crystals improve storage consistency and bioavailability for GABAA modulator drug use.

Formula I prodrugs improve STAT3 inhibitor solubility and stability across pH levels while preserving pharmacokinetic properties for formulation.

Selective GPR84 antagonists curb proinflammatory signaling while preserving broader immune function across inflammatory and fibrotic disorders.

Novel tetrapeptide kappa-opioid agonists preserve analgesic and anti-pruritic activity while reducing respiratory, addictive, and sedative side effects.

Novel GPR52 modulators use targeted structural tuning to improve cognitive and schizophrenia symptoms while limiting off-target GPCR effects.

Encapsulated cannabinoids with undenatured Type II collagen improve joint and muscle relief while limiting degradation and boosting bioavailability.

Specific CD marker profiling identifies mesenchymal stem cell-derived cells with strong neuronal regeneration activity for neurological treatment.

Targeting mutant IDH1 neoactivity, this case shows how a selective inhibitor composition lowers 2HG and helps limit cancer progression.

Camelid VHH conjugates target phosphorylated tau and cross the blood-brain barrier for sensitive MRI detection of tau lesions.

Modular AAV cassettes combine ITRs, promoters, introns, and polyA signals to deliver NPC1 and reduce cholesterol accumulation.

Focused SNP assays improve prediction of patient response to neurotransmitter transporter inhibitors, supporting personalized CNS treatment.

Selective GBA2 inhibitors use tuned molecular features to limit off-target enzymes and improve brain exposure for glucosylceramide disorders.

A modified memantine compound, FENM protects neurons, reduces oxidative stress and neuroinflammation, and preserves cognition at effective doses.

Psychedelics such as LSD or psilocybin are used to reduce tremors and abnormal movements while avoiding the side effects of standard drugs.

A peptide-guided lipid nanoparticle helps cyclosporine A cross the blood-brain barrier, target brain lesions, and reduce systemic side effects.

ALDH2-modulating compounds reduce alcohol consumption and cravings while balancing acetaldehyde-related side effects through dose adjustment.

Fc-engineered humanized anti-αβTCR antibodies suppress αβTCR-positive T cells while avoiding FcγR cross-linking and cytokine release.

A carbamate compound composition improves trigeminal neuralgia pain control with longer analgesic effect and fewer side-effect limits than carbamazepine.

An AAVhu68 capsid carrying functional SMN improves CNS transduction at lower vector doses, extending survival and motor function in SMA models.

Esterified cromolyn improves oral bioavailability and avoids inhaler-use barriers, enabling more consistent treatment delivery.

Light-activated bistable type II opsins target presynaptic terminals to suppress synaptic release with fast, reversible neural control.

Combining ponesimod with teriflunomide or leflunomide simplifies dosing while improving lymphocyte reduction and safety.

Pure dialkyl tryptamine compositions tune bioavailability and conversion to active forms, expanding therapeutic use across neuropsychiatric disorders.

A defined cytokine sequence enables reproducible human microglia differentiation from pluripotent stem cells for drug screening and treatment research.

Anhydrous intra-oral soft anticholinergic esters reduce saliva locally for hours while minimizing systemic and CNS side effects.

Using the BI03 probiotic strain, this case shows a drug-resistance-free approach to ease Parkinson's symptoms, neuroinflammation, and oxidative stress.

Engineered molar ratios of purified psilocybin derivatives and co-compounds improve dosing consistency and neurotransmitter modulation with fewer side effects.

Selective anti-PILRA antibodies bind human and cynomolgus PILRA variants while minimizing PILRB off-target binding for preclinical studies.

Alternating biodegradable and blank polymer layers enable controlled pulsed 5HT2A agonist microdosing without repeated patient dosing.

Using inert-gas crystallization and tailored solvents, this case improves reduced coenzyme Q10 purity, oxidation stability, and residue control.

Structural tetracycline changes block ribosome binding to curb AUD, withdrawal, pain, and inflammation without antibiotic activity.

Oral xanomeline and trospium beads balance muscarinic receptor efficacy with lower peripheral side effects through controlled release and ratio stability.

Three-times-daily cytisine offers a lower-cost nicotine cessation approach that improves abstinence and reduces smoking or vaping use.

Humanized anti-αβTCR antibodies preserve BMA031 binding while blocking FcγR binding to suppress T cells with lower cytokine release.

GV1001 suppresses osteoclastogenesis, gingipain expression, and inflammatory cytokines to help prevent periodontal progression and related disease.

A multi-agent oral composition combines D-glutamine, ginkgolide B, phosphatidylserine, and ascorbic acid to improve short-term memory and focus.

Selective IDO1 and TDO modulator compounds help rebalance tryptophan metabolism, reduce immunosuppression, and broaden disease treatment options.

CBD is used with fibroblasts and other regenerative cells to reduce disc inflammation and apoptosis while improving matrix repair.

A lactam bridge between residues 2 and 7 stabilizes amylin analogues in aqueous liquid formulations, reducing fibrillation and extending action.

A chimeric Aβ-tau antigen with a T cell epitope boosts antibody titers and clears both protein pathologies with fewer doses.

Taking MCTs about 30 minutes before a meal raises blood ketones more effectively than co-administration while reducing gastrointestinal discomfort.